305 related articles for article (PubMed ID: 35600411)
1. Recent Advances of Autophagy in Non-Small Cell Lung Cancer: From Basic Mechanisms to Clinical Application.
Guo W; Du K; Luo S; Hu D
Front Oncol; 2022; 12():861959. PubMed ID: 35600411
[TBL] [Abstract][Full Text] [Related]
2. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
4. Autophagy-related chemoradiotherapy sensitivity in non-small cell lung cancer (NSCLC).
Zadeh FA; Raji A; Ali SA; Abdelbasset WK; Alekhina N; Iswanto AH; Terefe EM; Jalil AT
Pathol Res Pract; 2022 May; 233():153823. PubMed ID: 35398616
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
[TBL] [Abstract][Full Text] [Related]
6. Autophagy modulates transforming growth factor beta 1 induced epithelial to mesenchymal transition in non-small cell lung cancer cells.
Alizadeh J; Glogowska A; Thliveris J; Kalantari F; Shojaei S; Hombach-Klonisch S; Klonisch T; Ghavami S
Biochim Biophys Acta Mol Cell Res; 2018 May; 1865(5):749-768. PubMed ID: 29481833
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Dominici C; Sgarioto N; Yu Z; Sesma-Sanz L; Masson JY; Richard S; Raynal NJ
Clin Epigenetics; 2021 Mar; 13(1):54. PubMed ID: 33691794
[TBL] [Abstract][Full Text] [Related]
8. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
Xiao Z; Li M; Zhang X; Rong X; Xu H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
[TBL] [Abstract][Full Text] [Related]
9. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
10. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
[TBL] [Abstract][Full Text] [Related]
11. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
13. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
14. 9za plays cytotoxic and proapoptotic roles and induces cytoprotective autophagy through the PDK1/Akt/mTOR axis in non-small-cell lung cancer.
Liu R; Chen Z; Yi X; Huang F; Hu G; Liu D; Li X; Zhou H; Liu Z
J Cell Physiol; 2019 Nov; 234(11):20728-20741. PubMed ID: 31004362
[TBL] [Abstract][Full Text] [Related]
15. VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.
Zhao Y; Guo S; Deng J; Shen J; Du F; Wu X; Chen Y; Li M; Chen M; Li X; Li W; Gu L; Sun Y; Wen Q; Li J; Xiao Z
Int J Biol Sci; 2022; 18(9):3845-3858. PubMed ID: 35813484
[TBL] [Abstract][Full Text] [Related]
16. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.
Zhu C; Zhuang W; Chen L; Yang W; Ou WB
Transl Lung Cancer Res; 2020 Feb; 9(1):111-138. PubMed ID: 32206559
[TBL] [Abstract][Full Text] [Related]
17. The biology and management of non-small cell lung cancer.
Herbst RS; Morgensztern D; Boshoff C
Nature; 2018 Jan; 553(7689):446-454. PubMed ID: 29364287
[TBL] [Abstract][Full Text] [Related]
18. C-myc/miR-150/EPG5 axis mediated dysfunction of autophagy promotes development of non-small cell lung cancer.
Li H; Liu J; Cao W; Xiao X; Liang L; Liu-Smith F; Wang W; Liu H; Zhou P; Ouyang R; Yuan Z; Liu J; Ye M; Zhang B
Theranostics; 2019; 9(18):5134-5148. PubMed ID: 31410206
[No Abstract] [Full Text] [Related]
19. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.
Cheng Y; Zhang T; Xu Q
MedComm (2020); 2021 Dec; 2(4):692-729. PubMed ID: 34977873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
